Tandem Diabetes Care reported third-quarter 2026 results for the period ended September 30, 2026, with worldwide sales up 14% to $283.7 million and a net loss of $7.1 million, compared with $21.2 million a year earlier. The company reaffirmed its full-year 2026 guidance, including sales of approximately $1.065 billion to $1.085 billion.
Worldwide sales rose 14% to $283.7 million; U.S. sales rose 9% to $191.0 million and international sales rose 26% to $92.6 million.
Gross margin was 57%, compared with 54% in the third quarter of 2025.
Operating loss was $2.4 million, compared with $22.9 million a year earlier; adjusted EBITDA was $18.0 million.
For 2026, the company reaffirmed sales guidance of $1.065 billion to $1.085 billion and adjusted EBITDA margin guidance of 5% to 6%.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Tandem Diabetes Care's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$1.01B
+7.9%
$-3.04
—
-20.2%
FY2024
$940.20M
+25.7%
$-1.47
—
-10.2%
FY2023
$747.72M
-6.7%
$-3.43
—
-29.8%
FY2022
$801.22M
+14.0%
$-1.47
-712.5%
-11.8%
FY2021
$702.80M
+40.9%
$0.24
—
2.2%
Frequently asked questions
When is Tandem Diabetes Care's next earnings date?
Tandem Diabetes Care has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Tandem Diabetes Care earn last quarter?
For the quarter ended Sep 2026, Tandem Diabetes Care reported diluted EPS of $-0.10 on revenue of $283.69M (+13.8%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.